Abstracts tagged "rheumatic disease and treatment options"

Abstract Number: 192 • 2017 ACR/ARHP Annual Meeting
Patient Education Materials in Rheumatology: Only Adequate at Best
Aleksander Lenert¹ and Sujin Kim², ¹Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY, ²Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY
Background/Purpose: Low health literacy and reading ability of rheumatologic patients is associated with poor outcomes [1]. In practice, patient education is commonly delivered via patient…
Abstract Number: 879 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment
Anne C. Bay-Jensen¹, Natasja Stæhr Gudman², Anne Sofie Siebuhr¹, Claus Christiansen³ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].